Trump signs MFN drug pricing executive order, NASDAQ biotech index jumps 4%
May 12, 2025
Key Points
- Trump's most-favored-nation drug pricing order ties U.S. government prices to the lowest paid by other developed nations, giving pharmaceutical companies 180 days to comply before import restrictions take effect.
- The NASDAQ biotech index jumped 4% despite the order, suggesting markets view price controls as less destructive than feared or expect companies to raise global prices rather than cut U.S. margins.
- The policy faces constitutional and legal challenges, and implementation remains structurally unclear—the order doesn't explicitly require domestic price cuts and doesn't specify whether it applies only to Medicare or commercial insurance.
Summary
Trump signed an executive order Monday tying U.S. government drug prices to the lowest prices paid by other developed countries. The NASDAQ biotech index jumped 4%, defying expectations that price controls would crater the sector.
The order directs U.S. trade representatives and the Commerce Department to challenge foreign policies that suppress drug prices. RFK Jr. has 30 days to negotiate with pharmaceutical companies on pricing, with a 180-day compliance window. If companies don't lower prices within that period, Kennedy gains authority to propose rules and import restrictions. The order's scope remains unclear—it doesn't specify whether changes apply only to Medicare or extend to commercial insurance.
Price disparities
Jardiance, a diabetes medication, costs $611 for a 30-day supply in the U.S., versus $70 in Switzerland and $35 in Japan. Trump framed the order as stopping American patients from subsidizing cheaper healthcare systems abroad.
Market reaction
The biotech rally contradicts conventional expectations. The pharmaceutical industry argues that price controls destroy margins and kill R&D incentives. PhRMA's Alex Shire called government price-setting "bad for American patients" and warned it mirrors "failed policies from abroad." Yet markets treated the order as less destructive than feared. One possibility is that the order may force clarity in a system already murky with rebates and hidden discounts. Alternatively, pharmaceutical companies may raise prices globally rather than accept domestic cuts.
Legal and legislative obstacles
MFN pricing will likely face constitutional and administrative-law challenges. Congress could embed the concept into legislation through Medicare price negotiation or international reference pricing, but that adds strain to reconciliation bills already fragile. Trump attempted rebate reform in his first term and failed.
The structural problem
The order doesn't require companies to lower U.S. prices; they could simply raise prices elsewhere. If they do, and if generic alternatives exist in foreign markets, they may maintain margins while ceding market share. The policy assumes pharmaceutical margins can absorb a rebalancing without gutting R&D or that the current system is already extracting excess rent.
MFN clauses are familiar in venture capital—Y Combinator adopted them years ago—but applying them to pharmaceuticals at scale works differently than in the startup context. The 30-day negotiation window may force genuine price disclosure in a system where net prices are notoriously opaque.